| Campo DC | Valor | Idioma |
|---|
| dc.contributor.author | Melo, Ailton de Souza | - |
| dc.contributor.author | Rodrigues, Bernardo | - |
| dc.contributor.author | Bar-Or, Amit | - |
| dc.creator | Melo, Ailton de Souza | - |
| dc.creator | Rodrigues, Bernardo | - |
| dc.creator | Bar-Or, Amit | - |
| dc.date.accessioned | 2011-12-11T14:09:06Z | - |
| dc.date.available | 2011-12-11T14:09:06Z | - |
| dc.date.issued | 2008 | - |
| dc.identifier.issn | 1678-4227 | - |
| dc.identifier.uri | http://www.repositorio.ufba.br/ri/handle/ri/4788 | - |
| dc.description | p. 8-10 | pt_BR |
| dc.description.abstract | Beta-interferon use in definite multiple sclerosis (MS) has been proven to modify clinical and magnetic resonance imaging outcome. We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the safety and efficacy of beta-interferon on the occurrence of relapses in patients with a first clinical event suggestive of MS. After two years of follow-up, interferon beta decreased the risk of conversion to clinically definite MS 0.51[0.39-0.65], and delayed the time to diagnosis up to 367 days. Side-effects were mild and self limited. Our findings support the efficacy of early treatment with beta-interferon in reducing conversion to clinically defined MS in patients with clinically isolated syndromes. | pt_BR |
| dc.language.iso | en | pt_BR |
| dc.subject | interferon | pt_BR |
| dc.subject | clinically isolated syndromes | pt_BR |
| dc.subject | multiple sclerosis | pt_BR |
| dc.subject | immunomodulating therapy | pt_BR |
| dc.title | Beta Interferons in Clinically Isolated Syndromes | pt_BR |
| dc.title.alternative | Arquivos de Neuro-Psiquiatria | pt_BR |
| dc.type | Artigo de Periódico | pt_BR |
| dc.identifier.number | 66(1) | pt_BR |
| Aparece nas coleções: | Artigo Publicado em Periódico (Faculdade de Medicina)
|
